|
|
 Previous Article | Table of Contents | Next Article 
Antibody-mediated marrow failure after allogeneic bone marrow
transplantation
AJ Barge, G Johnson, R Witherspoon and B Torok-Storb
Fred Hutchinson Cancer Research Center, Seattle.
Marrow graft failure observed in association with histocompatibility
differences between donor and recipient is often attributed to rejection
mediated by host-derived cytolytic T lymphocytes. The data presented in
this report indicate that persistent host antibodies specific for donor
antigen may also mediate graft failure, either by antibody-dependent
cell-mediated cytotoxicity (ADCC), or complement- mediated cytotoxicity. In
the case of HLA Class I disparity, where all donor cells express the target
antigen, the presence of alpha-donor antibody was associated with complete
graft failure and death. In the case of ABO blood group antigen disparity,
the presence of alpha-donor antibody resulted in erythroid hypoplasia. The
latter cases proved informative insofar as they established that host
antibodies could persist for more than 18 months after chemoradiotherapy
and impair marrow function.
Volume 74,
Issue 5,
pp. 1477-1480,
10/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Stussi, J. Halter, E. Bucheli, P. V. Valli, L. Seebach, J. Gmur, A. Gratwohl, U. Schanz, J. R. Passweg, and J. D. Seebach
Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins
Haematologica,
February 1, 2009;
94(2):
239 - 248.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Taylor, M. J. Ehrhardt, M. M. Roforth, J. M. Swedin, A. Panoskaltsis-Mortari, J. S. Serody, and B. R. Blazar
Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients
Blood,
February 1, 2007;
109(3):
1307 - 1315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Storek, F. Viganego, M. A. Dawson, M. M. P. T. Herremans, M. Boeckh, M. E. D. Flowers, B. Storer, W. I. Bensinger, R. P. Witherspoon, and D. G. Maloney
Factors affecting antibody levels after allogeneic hematopoietic cell transplantation
Blood,
April 15, 2003;
101(8):
3319 - 3324.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Peggs, E. C. Morris, P. D. Kottaridis, J. Geary, A. H. Goldstone, D. C. Linch, S. Mackinnon, C. D. Bolan, S. F. Leitman, L. M. Griffith, et al.
Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen
Blood,
May 29, 2002;
99(12):
4642 - 4644.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Bolan, S. F. Leitman, L. M. Griffith, R. A. Wesley, J. L. Procter, D. F. Stroncek, A. J. Barrett, and R. W. Childs
Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation
Blood,
September 15, 2001;
98(6):
1687 - 1694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mielcarek, W. Leisenring, B. Torok-Storb, and R. Storb
Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect
Blood,
August 1, 2000;
96(3):
1150 - 1156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. L. Colson, M. J. Schuchert, and S. T. Ildstad
The Abrogation of Allosensitization Following the Induction of Mixed Allogeneic Chimerism
J. Immunol.,
July 15, 2000;
165(2):
637 - 644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Koch and R. Korngold
A Synthetic CD4-CDR3 Peptide Analog Enhances Bone Marrow Engraftment Across Major Histocompatibility Barriers
Blood,
April 15, 1997;
89(8):
2880 - 2890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
